JP2002534394A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002534394A5 JP2002534394A5 JP2000592017A JP2000592017A JP2002534394A5 JP 2002534394 A5 JP2002534394 A5 JP 2002534394A5 JP 2000592017 A JP2000592017 A JP 2000592017A JP 2000592017 A JP2000592017 A JP 2000592017A JP 2002534394 A5 JP2002534394 A5 JP 2002534394A5
- Authority
- JP
- Japan
- Prior art keywords
- sub
- use according
- binding molecule
- group
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 description 31
- 102000038129 antigens Human genes 0.000 description 31
- 108091007172 antigens Proteins 0.000 description 31
- 239000000203 mixture Substances 0.000 description 22
- 201000010099 disease Diseases 0.000 description 9
- 206010030032 Ocular disorder Diseases 0.000 description 7
- 206010003816 Autoimmune disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 102100005310 CTLA4 Human genes 0.000 description 4
- 101700054183 CTLA4 Proteins 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical group CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 102000018358 Immunoglobulins Human genes 0.000 description 4
- 108060003951 Immunoglobulins Proteins 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- 230000000139 costimulatory Effects 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 201000009910 diseases by infectious agent Diseases 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 200000000018 inflammatory disease Diseases 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000003961 penetration enhancing agent Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 210000003560 Epithelium, Corneal Anatomy 0.000 description 3
- 206010023332 Keratitis Diseases 0.000 description 3
- 206010025425 Maculopathy Diseases 0.000 description 3
- 206010072736 Rheumatic disease Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 201000007032 bacterial conjunctivitis Diseases 0.000 description 3
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 3
- 201000008106 ocular cancer Diseases 0.000 description 3
- 230000002062 proliferating Effects 0.000 description 3
- 230000000552 rheumatic Effects 0.000 description 3
- 206010067817 Acute haemorrhagic conjunctivitis Diseases 0.000 description 2
- 102100019461 CD28 Human genes 0.000 description 2
- 101700033362 CD28 Proteins 0.000 description 2
- 102100013077 CD4 Human genes 0.000 description 2
- 101700022938 CD4 Proteins 0.000 description 2
- 101710040446 CD40 Proteins 0.000 description 2
- 102100013137 CD40 Human genes 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100003729 CD40LG Human genes 0.000 description 2
- 102100019451 CD80 Human genes 0.000 description 2
- 101700080477 CD80 Proteins 0.000 description 2
- 102100008191 CD8A Human genes 0.000 description 2
- 101700054655 CD8A Proteins 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010010755 Conjunctivitis viral Diseases 0.000 description 2
- UVYVLBIGDKGWPX-SPPYGRLSSA-N Digitonin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H](O)C[C@]3(C)[C@@H]4[C@H]([C@@H]5[C@H](O)[C@@H]6O[C@]7([C@@H](C)[C@@H]6[C@@]5(C)CC4)OC[C@H](C)CC7)CC[C@H]3C2)O[C@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1 UVYVLBIGDKGWPX-SPPYGRLSSA-N 0.000 description 2
- 229940012356 Eye Drops Drugs 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 102100004115 ICAM1 Human genes 0.000 description 2
- 101700051176 ICAM1 Proteins 0.000 description 2
- 102100001475 ITGB2 Human genes 0.000 description 2
- 101710006663 ITGB2 Proteins 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100008254 SELL Human genes 0.000 description 2
- 101710038663 SELL Proteins 0.000 description 2
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 2
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 2
- 208000005914 Viral Conjunctivitis Diseases 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000001809 detectable Effects 0.000 description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 2
- WIULKAASLBZREV-VROIVTGWSA-N dihydrocytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3\C=C/C[C@H](C)CCC[C@@H](O)CCC(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 WIULKAASLBZREV-VROIVTGWSA-N 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 108010085650 interferon gamma receptor Proteins 0.000 description 2
- 230000001530 keratinolytic Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Description
【特許請求の範囲】
【請求項１】
免疫グロブリンのFcを含まず、眼障害と関連のある標的抗原と免疫的に相互作用するサブ−免疫グロブリン抗原結合分子、眼または角膜上皮中への前記サブ−免疫グロブリン抗原結合分子の浸透を改良するための浸透増強剤、および担体を含む、眼障害を治療または診断するための局所組成物。
【請求項２】
免疫グロブリンのFcを含まず、眼中の標的抗原と免疫的に相互作用するサブ−免疫グロブリン抗原結合分子、眼または角膜上皮中への前記サブ−免疫グロブリン抗原結合分子の浸透を改良するための浸透増強剤、および製薬的に許容できる賦形剤、希釈剤または担体を含む、眼の局所投与用に製剤化された眼用医薬組成物。
【請求項３】
サブ−免疫グロブリン抗原結合分子が、合成されたFv断片、合成され安定化されたFv断片、一本鎖Fv断片またはミニボディを含む、請求項１または２記載の組成物。
【請求項４】
標的抗原が、ＭＨＣ分子、補助的刺激分子、接着分子、受容体関連分子、サイトカイン受容体及びウイルス表面抗原から成る群より選択される、請求項１〜３のいずれか１項記載の組成物。
【請求項５】
補助的刺激分子がＣＤ８０、ＣＤ８６及びＣＤ１５２から成る群より選択される、請求項４記載の組成物。
【請求項６】
接着分子が、ＣＤ１１、ＣＤ１８、ＣＤ５４及びＣＤ６２Ｌから成る群より選択される、請求項４または５記載の組成物。
【請求項７】
受容体関連分子が、ＣＤ３、ＣＤ４、ＣＤ８、ＣＤ２８、ＣＤ４０、ＣＤ４０Ｌ及びＣＴＬＡ４から成る群より選択される、請求項４〜６のいずれか１項記載の組成物。
【請求項８】
サイトカイン受容体が、インターロイキン２受容体、インターロイキン２受容体のサブユニット、及びインターフェロンγ受容体から成る群より選択される、請求項４〜７のいずれか１項記載の組成物。
【請求項９】
ウイルス表面抗原がヘルペスウイルス表面抗原を含む、請求項４〜８のいずれか１項記載の組成物。
【請求項１０】
ヘルペスウイルス表面抗原がｇＤ２又はｇＢ２である、請求項９記載の組成物。
【請求項１１】
サブ−免疫グロブリン抗原結合分子がその半減期を延長するために修飾されている、請求項１〜１０のいずれか１項記載の組成物。
【請求項１２】
サブ−免疫グロブリン抗原結合分子がポリエチレングリコールで化学的に修飾されている、請求項１１記載の組成物。
【請求項１３】
透増強剤が、カプリン酸、ＤＭＳＯ、ジヒドロサイトカラシンＢ、ジギトニン、界面活性剤及びそれらの任意の組合せから成る群より選択される、請求項１〜１２のいずれか１項記載の組成物。
【請求項１４】
イオン導入法用に製剤化された、請求項１〜１３のいずれか１項記載の組成物。
【請求項１５】
目薬またはコラーゲン・シールドの形態で製剤化された、請求項１〜１４のいずれか１項記載の組成物。
【請求項１６】
眼障害が、角膜移植拒絶反応、ブドウ膜炎、炎症性または感染性疾患、および自己免疫疾患からなる群より選ばれる、請求項１〜１５のいずれか１項記載の組成物。
【請求項１７】
炎症性または感染性疾患がウイルス性、細菌性若しくはクラミジア性結膜炎若しくは角膜炎、眼腫瘍、新生血管形成増殖病、新生血管形成黄斑症、リュウマチ性角膜融解疾患からなる群より選ばれる、請求項１６記載の組成物。
【請求項１８】
自己免疫疾患が眼類天疱瘡である、請求項１６記載の組成物。
【請求項１９】
サブ−免疫グロブリン抗原結合分子が前記分子に結合した検出可能な標識を有する、請求項１〜１８のいずれか１項記載の組成物。
【請求項２０】
標識が蛍光色素を含む、請求項１９記載の組成物。
【請求項２１】
蛍光色素がフルオレセインである、請求項２０記載の組成物。
【請求項２２】
免疫グロブリンのFcを含まず、眼障害と関連のある標的抗原と免疫的に相互作用するサブ−免疫グロブリン抗原結合分子の、該眼障害の治療用の医薬の調製のための使用であって、前記サブ−免疫グロブリン抗原結合分子が局所投与用に製剤化されている、前記使用。
【請求項２３】
免疫グロブリンのFcを含まず、眼障害の指標となる標的抗原と免疫的に相互作用するサブ−免疫グロブリン抗原結合分子の、該眼障害の診断用の医薬の調製のための使用であって、前記サブ−免疫グロブリン抗原結合分子が局所投与用に製剤化されている、前記使用。
【請求項２４】
サブ−免疫グロブリン抗原結合分子が、合成されたFv断片、合成され安定化されたFv断片、一本鎖Fv断片またはミニボディを含む、請求項２２または２３記載の使用。
【請求項２５】
標的抗原が、ＭＨＣ分子、補助的刺激分子、接着分子、受容体関連分子、サイトカイン受容体及びウイルス表面抗原から成る群より選択される、請求項２２〜２４のいずれか１項記載の使用。
【請求項２６】
補助的刺激分子がＣＤ８０、ＣＤ８６及びＣＤ１５２から成る群より選択される、請求項２５記載の使用。
【請求項２７】
接着分子が、ＣＤ１１、ＣＤ１８、ＣＤ５４及びＣＤ６２Ｌから成る群より選択される、請求項２５または２６記載の使用。
【請求項２８】
受容体関連分子が、ＣＤ３、ＣＤ４、ＣＤ８、ＣＤ２８、ＣＤ４０、ＣＤ４０Ｌ及びＣＴＬＡ４から成る群より選択される、請求項２５〜２７のいずれか１項記載の使用。
【請求項２９】
サイトカイン受容体が、インターロイキン２受容体、インターロイキン２受容体のサブユニット、及びインターフェロンγ受容体から成る群より選択される、請求項２５〜２８のいずれか１項記載の使用。
【請求項３０】
ウイルス表面抗原がヘルペスウイルス表面抗原を含む、請求項２５〜２９のいずれか１項記載の使用。
【請求項３１】
ヘルペスウイルス表面抗原がｇＤ２又はｇＢ２である、請求項３０記載の使用。
【請求項３２】
サブ−免疫グロブリン抗原結合分子がその半減期を延長するために修飾されている、請求項２２〜３１のずれか１項記載の使用。
【請求項３３】
サブ−免疫グロブリン抗原結合分子がポリエチレングリコールで化学的に修飾されている、請求項３２記載の使用。
【請求項３４】
眼または角膜上皮へのサブ−免疫グロブリン抗原結合分子の浸透を改良するために浸透増強剤と共に医薬が製剤化される、請求項２２〜３３のいずれか１項記載の使用。
【請求項３５】
浸透増強剤が、カプリン酸、ＤＭＳＯ、ジヒドロサイトカラシンＢ、ジギトニン、界面活性剤及びそれらの任意の組合せから成る群より選択される、請求項３４記載の使用。
【請求項３６】
医薬がイオン導入法用に製剤化される、請求項２２〜３５のいずれか１項記載の使用。
【請求項３７】
医薬が目薬またはコラーゲン・シールドの形態である、請求項２２〜３６のいずれか１項記載の使用。
【請求項３８】
サブ−免疫グロブリン抗原結合分子が前記分子に結合した検出可能な標識を有する、請求項２３〜３７のいずれか１項記載の使用。
【請求項３９】
標識が蛍光色素を含む、請求項３８記載の使用。
【請求項４０】
蛍光色素がフルオレセインである、請求項３９記載の使用。
【請求項４１】
眼障害が、角膜移植拒絶反応、ブドウ膜炎、炎症性または感染性疾患、および自己免疫疾患からなる群より選ばれる、請求項２２〜４０のいずれか１項記載の使用。
【請求項４２】
炎症性または感染性疾患がウイルス性、細菌性若しくはクラミジア性結膜炎若しくは角膜炎、眼腫瘍、新生血管形成増殖病、新生血管形成黄斑症、リュウマチ性角膜融解疾患からなる群より選ばれる、請求項４１記載の使用。
【請求項４３】
自己免疫疾患が眼類天疱瘡である、請求項４１記載の使用。
[Claims]
(1)
A sub-immunoglobulin antigen-binding molecule that is free of immunoglobulin Fc and immunologically interacts with a target antigen associated with ocular disorders, improving the penetration of said sub-immunoglobulin antigen-binding molecule into the eye or corneal epithelium A topical composition for treating or diagnosing an eye disorder, comprising a penetration enhancer, and a carrier.
(2)
A sub-immunoglobulin antigen-binding molecule that is free of immunoglobulin Fc and interacts immunologically with a target antigen in the eye, penetration to improve penetration of said sub-immunoglobulin antigen-binding molecule into the eye or corneal epithelium An ophthalmic pharmaceutical composition formulated for topical ocular administration, comprising a potentiator, and a pharmaceutically acceptable excipient, diluent or carrier.
(3)
3. The composition of claim 1 or 2, wherein the sub-immunoglobulin antigen binding molecule comprises a synthesized Fv fragment, a synthesized and stabilized Fv fragment, a single chain Fv fragment or a minibody.
(4)
The composition according to any one of claims 1 to 3, wherein the target antigen is selected from the group consisting of MHC molecules, costimulatory molecules, adhesion molecules, receptor-related molecules, cytokine receptors and virus surface antigens.
(5)
5. The composition of claim 4, wherein the costimulatory molecule is selected from the group consisting of CD80, CD86 and CD152.
6.
The composition according to claim 4 or 5, wherein the adhesion molecule is selected from the group consisting of CD11, CD18, CD54 and CD62L.
7.
The composition according to any one of claims 4 to 6, wherein the receptor-related molecule is selected from the group consisting of CD3, CD4, CD8, CD28, CD40, CD40L and CTLA4.
Claim 8.
The composition according to any one of claims 4 to 7, wherein the cytokine receptor is selected from the group consisting of an interleukin 2 receptor, a subunit of the interleukin 2 receptor, and an interferon gamma receptor.
9.
9. The composition according to any one of claims 4 to 8, wherein the virus surface antigen comprises a herpes virus surface antigen.
10.
The composition according to claim 9, wherein the herpes virus surface antigen is gD2 or gB2.
11.
11. The composition of any one of claims 1 to 10, wherein the sub-immunoglobulin antigen binding molecule has been modified to increase its half-life.
12.
12. The composition of claim 11, wherein the sub-immunoglobulin antigen binding molecule has been chemically modified with polyethylene glycol.
Claim 13
13. The composition according to any one of claims 1 to 12, wherein the permeation enhancer is selected from the group consisting of capric acid, DMSO, dihydrocytochalasin B, digitonin, a surfactant and any combination thereof.
14.
The composition according to any one of claims 1 to 13, which is formulated for iontophoresis.
15.
15. The composition according to any one of claims 1 to 14, formulated in the form of eye drops or a collagen shield.
16.
16. The composition according to any one of claims 1 to 15, wherein the ocular disorder is selected from the group consisting of corneal transplant rejection, uveitis, inflammatory or infectious diseases, and autoimmune diseases.
17.
17. The inflammatory or infectious disease is selected from the group consisting of viral, bacterial or chlamydial conjunctivitis or keratitis, ocular tumors, neovascular proliferative diseases, neovascular maculopathy, rheumatic keratolytic disease. A composition as described.
18.
17. The composition of claim 16, wherein the autoimmune disease is pemphigus ophthalmic.
(19)
19. The composition of any one of claims 1 to 18, wherein the sub-immunoglobulin antigen binding molecule has a detectable label attached to the molecule.
20.
20. The composition of claim 19, wherein the label comprises a fluorescent dye.
21.
21. The composition according to claim 20, wherein the fluorescent dye is fluorescein.
22.
Use of a sub-immunoglobulin antigen-binding molecule that does not comprise the immunoglobulin Fc and immunologically interacts with a target antigen associated with an ocular disorder, for the preparation of a medicament for the treatment of said ocular disorder, The use above, wherein the sub-immunoglobulin antigen binding molecule is formulated for topical administration.
23.
A use of a sub-immunoglobulin antigen-binding molecule that does not contain the immunoglobulin Fc and immunologically interacts with a target antigen that is indicative of an ocular disorder, for the preparation of a medicament for diagnosis of the ocular disorder, The use above, wherein the sub-immunoglobulin antigen binding molecule is formulated for topical administration.
24.
24. Use according to claim 22 or 23, wherein the sub-immunoglobulin antigen binding molecule comprises a synthetic Fv fragment, a synthesized and stabilized Fv fragment, a single chain Fv fragment or a minibody.
25.
25. Use according to any one of claims 22 to 24, wherein the target antigen is selected from the group consisting of MHC molecules, costimulatory molecules, adhesion molecules, receptor-related molecules, cytokine receptors and viral surface antigens.
26.
26. The use according to claim 25, wherein the costimulatory molecule is selected from the group consisting of CD80, CD86 and CD152.
27.
The use according to claim 25 or 26, wherein the adhesion molecule is selected from the group consisting of CD11, CD18, CD54 and CD62L.
28.
28. The use according to any one of claims 25 to 27, wherein the receptor associated molecule is selected from the group consisting of CD3, CD4, CD8, CD28, CD40, CD40L and CTLA4.
29.
29. The use according to any one of claims 25 to 28, wherein the cytokine receptor is selected from the group consisting of an interleukin 2 receptor, a subunit of an interleukin 2 receptor, and an interferon gamma receptor.
30.
30. Use according to any one of claims 25 to 29, wherein the virus surface antigen comprises a herpes virus surface antigen.
31.
31. The use according to claim 30, wherein the herpes virus surface antigen is gD2 or gB2.
32.
32. Use according to any one of claims 22 to 31, wherein the sub-immunoglobulin antigen binding molecule has been modified to extend its half-life.
33.
33. The use according to claim 32, wherein the sub-immunoglobulin antigen binding molecule is chemically modified with polyethylene glycol.
34.
34. Use according to any one of claims 22 to 33, wherein the medicament is formulated with a penetration enhancer to improve penetration of the sub-immunoglobulin antigen binding molecule into the eye or corneal epithelium.
35.
35. The use according to claim 34, wherein the penetration enhancer is selected from the group consisting of capric acid, DMSO, dihydrocytochalasin B, digitonin, a surfactant and any combination thereof.
36.
36. Use according to any one of claims 22 to 35, wherein the medicament is formulated for iontophoresis.
37.
37. Use according to any one of claims 22 to 36, wherein the medicament is in the form of eye drops or a collagen shield.
38.
38. Use according to any one of claims 23 to 37, wherein the sub-immunoglobulin antigen binding molecule has a detectable label attached to said molecule.
39.
39. Use according to claim 38, wherein the label comprises a fluorescent dye.
40.
40. Use according to claim 39, wherein the fluorescent dye is fluorescein.
41.
41. The use according to any one of claims 22 to 40, wherein the ocular disorder is selected from the group consisting of corneal transplant rejection, uveitis, inflammatory or infectious diseases, and autoimmune diseases.
42.
42. The inflammatory or infectious disease is selected from the group consisting of viral, bacterial or chlamydial conjunctivitis or keratitis, ocular tumor, neovascular proliferative disease, neovascular maculopathy, rheumatic keratolytic disease. Use of the description.
Claim 43
42. The use according to claim 41, wherein the autoimmune disease is pemphigus ophthalmic.
典型的な病気又は障害には、角膜移植拒絶反応、ブドウ膜炎、任意の眼の感染、ウイルス性（ヘルペス性角膜炎及びアデノウイルス性）、細菌性若しくはクラミジア性結膜炎などの炎症性及び感染性疾患、眼腫瘍、糖尿病網膜症などの新生血管形成増殖病、新生血管形成黄斑症、リュウマチ性角膜融解疾患及び眼類天疱瘡などの自己免疫障害が含まれる。 Typical diseases or disorders include corneal transplant rejection, uveitis, any ocular infection, inflammatory and infectious such as viral (herpes keratitis and adenoviral), bacterial or chlamydial conjunctivitis Autoimmune disorders such as diseases, ocular tumors, neovascular proliferative diseases such as diabetic retinopathy, neovascular maculopathy, rheumatic corneal lysis disease and ocular pemphigus .
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU8033 | 1988-05-03 | ||
| AUPP8033 | 1999-01-05 | ||
| AUPP8033A AUPP803399A0 (en) | 1999-01-05 | 1999-01-05 | Novel therapeutic and diagnostic agent for ocular disorders |
| AU3305 | 1999-10-07 | ||
| AUPQ3305 | 1999-10-07 | ||
| AUPQ3305A AUPQ330599A0 (en) | 1999-10-07 | 1999-10-07 | Novel agents for treatment and diagnosis of ocular disorders |
| PCT/AU1999/001163 WO2000040262A1 (en) | 1999-01-05 | 1999-12-24 | Novel agents and methods for treatment and diagnosis of ocular disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011014766A Division JP5703039B2 (en) | 1999-01-05 | 2011-01-27 | Novel drugs and methods for treating and diagnosing eye disorders |
| JP2013208202A Division JP2013256541A (en) | 1999-01-05 | 2013-10-03 | New agent and method for treating and diagnosing ocular disorder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002534394A JP2002534394A (en) | 2002-10-15 |
| JP2002534394A5 true JP2002534394A5 (en) | 2006-12-21 |
| JP5483789B2 JP5483789B2 (en) | 2014-05-07 |
Family
ID=25645965
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000592017A Expired - Lifetime JP5483789B2 (en) | 1999-01-05 | 1999-12-24 | Novel drugs and methods for treating and diagnosing eye disorders |
| JP2011014766A Expired - Lifetime JP5703039B2 (en) | 1999-01-05 | 2011-01-27 | Novel drugs and methods for treating and diagnosing eye disorders |
| JP2013208202A Withdrawn JP2013256541A (en) | 1999-01-05 | 2013-10-03 | New agent and method for treating and diagnosing ocular disorder |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011014766A Expired - Lifetime JP5703039B2 (en) | 1999-01-05 | 2011-01-27 | Novel drugs and methods for treating and diagnosing eye disorders |
| JP2013208202A Withdrawn JP2013256541A (en) | 1999-01-05 | 2013-10-03 | New agent and method for treating and diagnosing ocular disorder |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6773916B1 (en) |
| EP (1) | EP1140170B1 (en) |
| JP (3) | JP5483789B2 (en) |
| AT (1) | ATE330631T1 (en) |
| CA (1) | CA2348488C (en) |
| DE (1) | DE69932084T2 (en) |
| DK (1) | DK1140170T3 (en) |
| NZ (1) | NZ511219A (en) |
| WO (1) | WO2000040262A1 (en) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| WO2000040262A1 (en) * | 1999-01-05 | 2000-07-13 | The Flinders University Of South Australia | Novel agents and methods for treatment and diagnosis of ocular disorders |
| WO2001030386A1 (en) * | 1999-10-22 | 2001-05-03 | Biogen, Inc. | Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye |
| CA2432978C (en) | 2000-12-22 | 2012-08-28 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
| JP2002208294A (en) * | 2001-01-12 | 2002-07-26 | Toshiba Corp | Semiconductor memory having redundancy system |
| WO2002089615A2 (en) * | 2001-05-03 | 2002-11-14 | Novartis Ag | Anti-ige antibody to treat ocular allergies |
| JP4838968B2 (en) * | 2001-09-28 | 2011-12-14 | 参天製薬株式会社 | Intraocular injection containing drug-polyethylene glycol conjugate |
| JP2006524036A (en) | 2002-11-08 | 2006-10-26 | アブリンクス エン．ヴェー． | Single domain antibodies targeting tumor necrosis factor alpha and uses thereof |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| AU2003286003B2 (en) * | 2002-11-08 | 2011-05-26 | Ablynx N.V. | Stabilized single domain antibodies |
| EP1682537B1 (en) | 2003-11-05 | 2012-03-28 | SARcode Bioscience Inc. | Modulators of cellular adhesion |
| EP1758998B1 (en) * | 2004-01-30 | 2010-12-15 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
| PL2444079T3 (en) | 2005-05-17 | 2017-07-31 | Sarcode Bioscience Inc. | Compositions and Methods for Treatment of Eye Disorders |
| US9198981B2 (en) * | 2006-02-01 | 2015-12-01 | The University Of Kentucky | Modulation of angiogenesis |
| US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| US20070218007A1 (en) * | 2006-03-17 | 2007-09-20 | Allergan, Inc. | Ophthalmic visualization compositions and methods of using same |
| WO2007131050A2 (en) * | 2006-05-02 | 2007-11-15 | Georgia Tech Research Corporation | Method for drug delivery to ocular tissue using microneedle |
| US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
| US20080138334A1 (en) | 2006-05-31 | 2008-06-12 | Sabbadini Roger A | Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same |
| US9274130B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
| US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
| SI2046382T1 (en) | 2006-07-10 | 2016-12-30 | ESBATech an Alcon Biomedical Research Unit LLC | scFv ANTIBODIES WHICH PASS EPITHELIAL AND/OR ENDOTHELIAL LAYERS |
| US20080031903A1 (en) * | 2006-07-27 | 2008-02-07 | Andrea Gambotto | Method of treating ocular infections |
| JP5795833B2 (en) | 2006-10-27 | 2015-10-14 | エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． | Compositions and methods for binding sphingosine-1-phosphate |
| US20090156881A1 (en) * | 2007-10-15 | 2009-06-18 | Stokes John P | Convergent well irradiating plaque for choroidal melanoma |
| US20090155176A1 (en) | 2007-10-19 | 2009-06-18 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
| US20090258070A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Topical LFA-1 antagonists for use in localized treatment of immune related disorders |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US20090258069A1 (en) * | 2008-04-15 | 2009-10-15 | John Burnier | Delivery of LFA-1 antagonists to the gastrointestinal system |
| WO2009128933A1 (en) * | 2008-04-15 | 2009-10-22 | Sarcode Corporation | Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders |
| US7772006B2 (en) * | 2008-08-21 | 2010-08-10 | Paul Tornambe | Agent detection and/or quantitation in a biological fluid |
| US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
| US20110033389A1 (en) * | 2009-04-29 | 2011-02-10 | Zhifeng Chen | Modified antibodies for passive immunotherapy |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US8735648B2 (en) | 2010-02-08 | 2014-05-27 | Cornell University | Model system of Acanthamoeba keratitis syndrome and method for selecting a treatment thereof |
| ES2604837T3 (en) | 2012-02-02 | 2017-03-09 | Esbatech - A Novartis Company Llc | Sustained release formulation containing antibodies for ocular administration |
| EP3715345B1 (en) | 2012-07-25 | 2024-04-10 | Novartis AG | Preparation of lfa-1 inhibitor |
| KR20150083117A (en) | 2012-11-08 | 2015-07-16 | 클리어사이드 바이오메디컬, 인코포레이드 | Methods and devices for the treatment of ocular disease in human subjects |
| CA2898354C (en) * | 2013-01-25 | 2017-11-21 | Thymon, Llc | Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease |
| AU2013382142B2 (en) * | 2013-03-14 | 2016-12-22 | Ecole Nationale D'ingenieurs De Saint-Etienne | Medical device intended for the long-term storage of a cornea, or for ex vivo experimentation on a human or animal cornea |
| CN110302004B (en) | 2013-05-03 | 2023-04-28 | 科尼尔赛德生物医学公司 | Apparatus and method for ocular injection |
| WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
| US20160310417A1 (en) | 2013-12-20 | 2016-10-27 | Emory University | Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents |
| MX2016017028A (en) | 2014-06-20 | 2017-08-07 | Clearside Biomedical Inc | Variable diameter cannula and methods for controlling insertion depth for medicament delivery. |
| JP6499290B2 (en) | 2014-09-09 | 2019-04-10 | ヘレラ アルトゥーロ ソリス | Methods for the treatment and prevention of eye diseases, eye disorders and symptoms with melanin and melanin analogs, precursors and derivatives |
| USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
| AU2016209550A1 (en) * | 2015-01-20 | 2017-08-03 | Veloce Biopharma Llc | Novel iodophor composition and methods of use |
| EP3173098A1 (en) * | 2015-11-27 | 2017-05-31 | Assistance Publique-Hopitaux De Paris | Immunostimulatory compositions |
| EP3413851B1 (en) | 2016-02-10 | 2023-09-27 | Clearside Biomedical, Inc. | Packaging |
| US10443032B2 (en) * | 2016-04-19 | 2019-10-15 | The Government Of The United States, As Represented By The Secretary Of The Army | Device and method for isolation of corneal endothelial cells |
| CA3062845A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
| US10973681B2 (en) | 2016-08-12 | 2021-04-13 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
| CN109706238B (en) | 2017-10-26 | 2023-04-07 | 珠海岐微生物科技有限公司 | Method for detecting and treating age-related macular degeneration |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS568324A (en) * | 1979-07-04 | 1981-01-28 | Mochida Pharmaceut Co Ltd | Infectious disease remedy for external and ophthalmologic application |
| US5616122A (en) * | 1986-11-04 | 1997-04-01 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
| JPH07121879B2 (en) * | 1986-11-14 | 1995-12-25 | 富士レビオ株式会社 | Immunoglobulin preparation for eye drops |
| EP0444778A1 (en) * | 1990-02-14 | 1991-09-04 | Alcon Laboratories, Inc. | Use of alkyl saccharides to enhance the penetration of drugs |
| EP0610290B1 (en) * | 1991-10-04 | 1999-05-26 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Manufacture of a medicament for treatment of ocular inflammation by blockage of cell adhesion molecules |
| US5837821A (en) * | 1992-11-04 | 1998-11-17 | City Of Hope | Antibody construct |
| EP0675734A4 (en) * | 1992-12-21 | 1997-05-07 | Tanox Biosystems Inc | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT. |
| US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| JPH11510185A (en) * | 1995-08-07 | 1999-09-07 | シェーリング コーポレイション | Treatment of inflammatory conditions of the eye with interleukin-10 |
| EP0918858A1 (en) * | 1996-05-10 | 1999-06-02 | Biogen, Inc. | Common gamma chain blocking agents |
| JPH1180024A (en) * | 1997-09-12 | 1999-03-23 | Toagosei Co Ltd | Corneal vascular rebirth inhibitor |
| TWI259837B (en) * | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| WO2000040262A1 (en) * | 1999-01-05 | 2000-07-13 | The Flinders University Of South Australia | Novel agents and methods for treatment and diagnosis of ocular disorders |
-
1999
- 1999-12-24 WO PCT/AU1999/001163 patent/WO2000040262A1/en active IP Right Grant
- 1999-12-24 DE DE69932084T patent/DE69932084T2/en not_active Expired - Lifetime
- 1999-12-24 DK DK99966798T patent/DK1140170T3/en active
- 1999-12-24 JP JP2000592017A patent/JP5483789B2/en not_active Expired - Lifetime
- 1999-12-24 US US09/857,399 patent/US6773916B1/en not_active Expired - Lifetime
- 1999-12-24 CA CA2348488A patent/CA2348488C/en not_active Expired - Lifetime
- 1999-12-24 AT AT99966798T patent/ATE330631T1/en not_active IP Right Cessation
- 1999-12-24 EP EP99966798A patent/EP1140170B1/en not_active Expired - Lifetime
- 1999-12-24 NZ NZ511219A patent/NZ511219A/en not_active IP Right Cessation
-
2011
- 2011-01-27 JP JP2011014766A patent/JP5703039B2/en not_active Expired - Lifetime
-
2013
- 2013-10-03 JP JP2013208202A patent/JP2013256541A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002534394A5 (en) | ||
| CA2348488A1 (en) | Novel agents and methods for treatment and diagnosis of ocular disorders | |
| US11559564B2 (en) | Use of a VEGF antagonist to treat angiogenic eye disorders | |
| Forman et al. | Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?[see comments] | |
| US20230109980A1 (en) | Methods for modulating an immune response | |
| JP2546544B2 (en) | Methods and compositions for promoting immune enhancement | |
| US11267888B2 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against CD28 | |
| US10800828B2 (en) | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer | |
| EP1470159B1 (en) | Antibody to latent membrane proteins and uses thereof | |
| US20230257464A1 (en) | Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist | |
| US9624276B2 (en) | Peptidic chimeric antigen receptor T cell switches and uses thereof | |
| US8716452B2 (en) | Fully human antibodies against human 4-1BB | |
| WO2018012895A1 (en) | Immune cell surmounting immune checkpoint and pharmaceutical composition containing same immune cell | |
| US20180221503A1 (en) | Compositions and methods for immuno-oncology therapies | |
| CA2807585A1 (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| WO2012122396A1 (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| US20210284712A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2020535811A5 (en) | ||
| WO2003038062A2 (en) | Generation of use of tc1 and tc2 cells | |
| WO2000073335A1 (en) | Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy | |
| US20020051783A1 (en) | Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means | |
| JP2019150058A5 (en) | ||
| KR101897464B1 (en) | Immune cell overcoming immune checkpoint signaling and pharmaceutical composition comprising said immune cell | |
| JP2023518578A (en) | Compositions and methods for targeting HPV-infected cells | |
| CA3160151A1 (en) | Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection |